AbCellera Biologics Long Term Debt

AbCellera Biologics posts a long-term debt of $130M as of March 2026. That compares with $63M in the prior-year period — up 112.5% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, AbCellera Biologics's long-term debt was $63M. The latest reading is $130M — a 112.5% year-over-year increase (period ending March 2026). Use the history and growth charts on this page for a longer lookback.

Long-Term Debt is one piece of AbCellera Biologics's financial statement story. At $130M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for ABCL's long-term debt usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; AbCellera Biologics's other metric pages and overview cover the third.